Education
About Us
Working with TipRanks
Follow Us
Co-Diagnostics Inc (CODX)
OTHER OTC:CODX
CODX Stock Chart & Stats
$0.26
-$0.07(-8.42%)
At close: 4:00 PM EST
$0.26
-$0.07(-8.42%)
Day’s Range― - ―
52-Week Range$2.12 - $46.50
Previous CloseN/A
Volume146.43K
Average Volume (3M)10.09M
Market Cap
$4.89M
Enterprise Value-$7.52M
Total Cash (Recent Filing)$11.44M
Total Debt (Recent Filing)$1.47M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 19, 2026EPS Estimate
-3.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.80
Shares Outstanding2,095,031
10 Day Avg. Volume1,334,715
30 Day Avg. Volume10,088,102
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.42
Price to Sales (P/S)5.81
P/FCF Ratio-0.76
Enterprise Value/Market Cap-1.54
Enterprise Value/Revenue-14.80
Enterprise Value/Gross Profit-43.49
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$5.00Price Target Upside1823.08% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-12.15
Revenue Forecast (FY)$576.20K
Bulls Say, Bears Say
Bulls Say
Affordable High-performance DevicePCR Pro delivers laboratory-grade RT‑PCR accuracy in a compact, lower-cost desktop form factor, enabling expanded point-of-care use without sacrificing diagnostic quality.
International Market Expansion Via PartnershipsStrategic joint ventures and distribution agreements targeting India, Saudi Arabia and MENA markets could unlock placements in clinical programs and expand revenue beyond prior COVID‑19 kit channels.
Technology DifferentiationCo‑Primer chemistry uses unique short primers that reduce non-specific binding, potentially improving PCR specificity and lowering false positives compared with standard assays.
Bears Say
Capital Needs And Dilution RiskNeed to raise additional capital at current share levels could lead to shareholder dilution and place downward pressure on the stock if financing is required on unfavorable terms.
Exchange Listing UncertaintyOngoing listing and regulatory uncertainty, including the risk of delisting from a major exchange, can erode investor confidence and restrict access to public capital markets.
Regulatory And Clinical Approval RiskThe ABC multiplex test lacks FDA clearance for US use and remains subject to clinical performance evaluations, creating the risk of delayed or denied regulatory approval that would limit commercialization.
Co-Diagnostics News
CODX FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was $2.12 and its highest was $46.50 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is $4.89M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Mar 19, 2026 which is in 19 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Nov 13, 2025. The company reported -$4.8 earnings per share for the quarter, beating the consensus estimate of -$5.7 by $0.9.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -3.6.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 2,095,031 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$4.8 in its last earnings report, beating expectations of -$5.7. Following the earnings report the stock price went down -10.941%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in CODX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
CODX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the company's strategic initiatives and international expansion efforts as major drivers of future growth. However, significant financial challenges remain, with declining revenue and continued net losses, albeit with improved operational efficiency.View all CODX earnings summariesCODX Stock 12 Month Forecast
Average Price Target
$5.00
▲(1823.08% Upside)
Technical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Ownership Overview
Currently, No data available
---